SIRO Clinpharm (SIRO), a leading multinational Contract Research Organization (CRO), announced signing of strategic alliance with Advanced Clinical Trial Solutions LLC (ACT Solutions), Flemington, New Jersey, USA, a service provider in oncology drug development with a business concentration in North America.
This alliance will enable SIRO to expand its Oncology Clinical development and patient recruitment expertise to North America. ACT Solutions and its clients will benefit by gaining access to SIRO's clinical study management, patient recruitment, data management, biostatistics and medical writing capabilities in India and European countries.
"We are delighted to add ACT Solution's North American expertise in our service offering to our customers," said Dr Chetan Tamhankar, COO of SIRO Clinpharm group. "This alliance is the first step for Siro in creating delivery capabilities in North America."
Patricia Devitt Risse, president of ACT Solutions LLC commented, "We are excited about aligning our strengths in Oncology with SIRO's international delivery capabilities. This step addresses the changing dynamics of the Clinical Research sector. We remain committed to providing a level of expertise and service that built our reputation and loyal client base to this point and this alliance expands our ability to deliver capabilities in Europe and India."
Patricia Terek, president of SIRO Clinpharm, USA said, "This step addresses growing needs of our Oncology Customers to have access to operational capabilities in North America. We are excited to offer the Clinical development expertise by Advanced Clinical Trial ACT Solutions in North America to our customers globally.
SIRO is a leading multinational contract research organization. With a presence in over 15 countries across North America, Europe and Asia, SIRO offers global bio-technology and pharmaceutical companies end to end clinical trial services.
ACT Solutions is a privately held company that is devoted to operational excellence in global oncology drug development.